All PlansCoverageMedium impact
Voluntary market withdrawal: Oxbryta (Pfizer – October)
UPMC Health Plan·Hematology, Oncology, Pediatrics +2 more·Pharmacy
We identified it
Jun 20, 2026
Summary
Pfizer has voluntarily withdrawn Oxbryta (used for sickle cell disease) from the market due to safety concerns showing risks outweigh benefits. Healthcare providers should immediately stop prescribing Oxbryta and transition patients to alternative FDA-approved sickle cell treatments.
Action Required
Immediately: Providers must stop prescribing Oxbryta and contact current patients taking this medication to discuss alternative treatment options. Update EMR to flag Oxbryta as withdrawn and remove from formulary lists. Billing team should verify no pending claims for Oxbryta and coordinate with pharmacy for patient transitions to alternative sickle cell medications.